HCW Biologics Inc (HCWB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
HCW Biologics Inc stock (HCWB) is currently trading at $0.39. HCW Biologics Inc PS ratio (Price-to-Sales) is 10.07. Analyst consensus price target for HCWB is $35.00. WallStSmart rates HCWB as Sell.
- HCWB PE ratio analysis and historical PE chart
- HCWB PS ratio (Price-to-Sales) history and trend
- HCWB intrinsic value — DCF, Graham Number, EPV models
- HCWB stock price prediction 2025 2026 2027 2028 2029 2030
- HCWB fair value vs current price
- HCWB insider transactions and insider buying
- Is HCWB undervalued or overvalued?
- HCW Biologics Inc financial analysis — revenue, earnings, cash flow
- HCWB Piotroski F-Score and Altman Z-Score
- HCWB analyst price target and Smart Rating
HCW Biologics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
HCW Biologics Inc (HCWB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
HCW Biologics Inc (HCWB) Key Strengths (0)
Supporting Valuation Data
HCW Biologics Inc (HCWB) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -98.90%, a shrinking business
Very expensive at 10.1x annual revenue
Very low institutional interest at 2.24%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
HCW Biologics Inc (HCWB) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (10.07), Price/Book (2.80) suggest expensive pricing. Growth concerns include Revenue Growth at -98.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -27726.00%, Operating Margin at -52887.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -27726.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -98.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HCWB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HCWB's Price-to-Sales ratio of 10.07x trades at a 19% premium to its historical average of 8.44x (71th percentile). The current valuation is 20% below its historical high of 12.61x set in Mar 2026, and 140% above its historical low of 4.2x in Feb 2026. Over the past 12 months, the PS ratio has expanded from ~4.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for HCW Biologics Inc (HCWB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
HCW Biologics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 832,840 with 99% decline year-over-year.
Key Findings
Spending 155% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 99% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact HCW Biologics Inc.
Bottom Line
HCW Biologics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About HCW Biologics Inc(HCWB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
HCW Biologics Inc is an innovative biotechnology firm at the forefront of developing novel immunotherapies and vaccine technologies targeting critical health challenges, including cancer and infectious diseases. Utilizing proprietary platforms that unlock the potential of the immune system, the company aims to deliver transformative biopharmaceutical solutions. With a robust pipeline of clinical candidates and strategic collaborations, HCW Biologics is well-positioned to drive advancements in patient care while addressing significant unmet medical needs, making it an attractive investment prospect for institutional investors in the growing biotechnology landscape.